The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Vasilyev N.V.

Cancer Research Institute of Tomsk National Research Medical Center

Vtorushin S.V.

Cancer Research Institute of Tomsk National Research Medical Center;
Siberian State Medical University

Maltseva A.A.

Cancer Research Institute of Tomsk National Research Medical Center

Sannikova A.V.

City Clinical Hospital No 3 named after B.I. Alperovich

Atypical fibroxanthoma

Authors:

Vasilyev N.V., Vtorushin S.V., Maltseva A.A., Sannikova A.V.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2023;85(5): 65‑72

DOI: 10.17116/patol20238505165

Views: 1305

Downloaded: 20

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Vasilyev NV, Vtorushin SV, Maltseva AA, Sannikova AV. Atypical fibroxanthoma. Russian Journal of Archive of Pathology. 2023;85(5):65‑72. (In Russ.)
https://doi.org/10.17116/patol20238505165

Подписка 2025 (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Close metadata
Recommended articles:
Labo­ratory diagnostics of «key» sexually transmitted infe­ctions (literature review). Part 1. Russian Journal of Clinical Dermatology and Vene­reology. 2023;(6):643-650
Labo­ratory diagnostics of neurosyphilis: ways of opti­mization. Part 1. «Classical» research methods. Russian Journal of Clinical Dermatology and Vene­reology. 2023;(6):652-660
Endo­scopic submucosal dissection in the practice of a colo­proctological hospital. The first resu­lts of a single-center trial. Endo­scopic Surgery. 2023;(6):52-61
Use of Atezolizumab in patients with adva­nced small cell lung cancer. P.A. Herzen Journal of Onco­logy. 2023;(6):63-67
Cyto­logic and immu­nohistochemical study on cell blocks of effu­sion fluids in patients with serous adenocarcinoma of the ovary. Labo­ratory Service. 2023;(4):18-22
Serum neurofilament light chains in asse­ssing the course of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):89-93
Plasma and sali­vary acetylcholinesterase acti­vity in amyotrophic late­ral scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):128-134
Diagnostics of HIV-infection in the Chechen Repu­blic: current state and prospects. Russian Journal of Preventive Medi­cine. 2024;(1):17-24
Analytical review of respiratory infe­ctions role in patients with chro­nic obstructive pulmonary disease and asthma. Part 1. Characteristics of respiratory infe­ctions and their long-term consequences. Russian Journal of Preventive Medi­cine. 2024;(1):90-96
Endo­bronchial hama­rtoma. P.A. Herzen Journal of Onco­logy. 2024;(1):59-62

Atypical fibroxanthoma (AFX) is a rare skin tumor characterized by a combination of a «malignant» morphological features and non-aggressive clinical course. Diagnosing AFX is challenging due to histological «diversity» and heterogeneous immunophenotype. The presented review describes the history and evolution of AFX as a nosological form of cancer, its histogenetic origin, pathogenesis and biological potential. The clinical, morphological, immunohistochemical, molecular cytogenetic characteristics and histological subtypes of the tumor as well as differential diagnosis have been presented in detail.

Keywords:

atypical fibroxanthoma
histology
immunohistochemistry
characteristics
diagnosis
prognosis

Authors:

Vasilyev N.V.

Cancer Research Institute of Tomsk National Research Medical Center

Vtorushin S.V.

Cancer Research Institute of Tomsk National Research Medical Center;
Siberian State Medical University

Maltseva A.A.

Cancer Research Institute of Tomsk National Research Medical Center

Sannikova A.V.

City Clinical Hospital No 3 named after B.I. Alperovich

Received:

26.05.2023

Accepted:

21.06.2023

List of references:

  1. López L, Vélez R. Atypical fibroxanthoma. Arch Pathol Lab Med. 2016;140(4):376-379.  https://doi.org/10.5858/arpa.2014-0495-RS
  2. Ziemer M. Atypical fibroxanthoma. J Dtsch Dermatol Ges. 2012; 10(8):537-550.  https://doi.org/10.1111/j.1610-0387.2012.07980.x
  3. Oshiro Y, Fukuda T, Tsuneyoshi M. Atypical fibroxanthoma versus benign and malignant fibrous histiocytoma. A comparative study of their proliferative activity using MIB-1, DNA flow cytometry, and p53 immunostaining. Cancer. 1995;75(5):1128-1134. https://doi.org/10.1002/1097-0142(19950301)75:5<1128::aid-cncr2820750512>3.0.co;2-h
  4. Vandergriff TW, Reed JA, Orengo IF. An unusual presentation of atypical fibroxanthoma. Dermatol Online J. 2008;14(1):6. 
  5. Gru AA, Cruz DJ. Atypical fibroxanthoma: a selective review. Semin Diagn Pathol. 2013;30(1):4-12.  https://doi.org/10.1053/j.semdp.2012.01.001
  6. Tos APD. Atypical fibroxanthoma. In: Tos APD, Hogendoom PCW. Soft Tissue and Bone. Evolving concepts in mesenchymal tumors of the skin. 2013: 351. Available at: evolving concepts in mesenchymal tumors of the skin — European... (yumpu.com).
  7. Scolyer RA, Murali R, McCarthy SW, Thompson JF. Atypical fibroxanthoma: differential diagnosis from other sarcomatoid skin lesions. Diagn Histopathol. 2010;16(9):401-408.  https://doi.org/10.1016/j.mpdhp.2010.06.007
  8. Katafygiotis P. Clear cell atypical fibroxanthoma: a case report and review of the literature. World Acad Sci J. 2021;3(4):1-8.  https://doi.org/10.3892/wasj.2021.109
  9. Griewank KG, Wiesner T, Murali R, Pischler C, Müller H, Koelsche C, Möller I, Franklin C, Cosgarea I, Sucker A, et al. Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles. Mod Pathol. 2018;31(3):418-428.  https://doi.org/10.1038/modpathol.2017.146
  10. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. 5th ed. Vol. 3. France, Lyon: International Agency for Research on Cancer; 2020.
  11. WHO Classification of tumours. WHO classification of skin tumours. 4th ed. Vol. 11. France, Lyon: International Agency for Research on Cancer; 2018.
  12. New D, Bahrami S, Malone J, Callen JP. Atypical fibroxanthoma with regional lymph node metastasis. Report of a case and review of the literature. Arch Dermatol. 2010;146(12):1399-1404. https://doi.org/10.1001/archdermatol.2010.206
  13. Koch M, Freundl AJ, Agaimy A, Kiesewetter F, Künzel J, Cicha I, Alexiou C. Atypical fibroxanthoma — histological diagnosis, immunohistochemical markers and concepts of therapy. Anticancer Res. 2015;35(11):5717-5735.
  14. Ríos-Vinuela E, Benaven MP, Monteagudo C, Nagorea E, Sanmartín O. Atypical fibroxanthoma and pleomorphic dermal sarcoma: a two-center retrospective study of 74 cases. Actas Dermosifiliogr. 2022;113(6):654-656.  https://doi.org/10.1016/j.ad.2021.09.008
  15. Helbig D, Ziemer M, Dippel E, Erdmann M, Hillen U, Leiter U, Mentzel T, Osterhoff G, Ugurel S, Utikal J, et al. S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS). J Dtsch Dermatol Ges. 2022;20(2):235-243.  https://doi.org/10.1111/ddg.14700
  16. Hanlon A, Stasko T, Christiansen D, Cyrus N, Galan A. LN2, CD10, and ezrin do not distinguish between atypical fibroxanthoma and undifferentiated pleomorphic sarcoma or predict clinical outcome. Dermatol Surg. 2017;43(3):431-436.  https://doi.org/10.1097/dss.0000000000001000
  17. Merati M, Scott J, Honda K, Bordeaux J. Atypical fibroxanthoma invading parietal bone. Dermatol Surg. 2018;44(12):1644-1646. https://doi.org/10.1097/DSS.0000000000001467
  18. McClure E, Carr MJ, Patel A, Hussnain Naqvi SM, Kim Y, Harrington M, Cruse W, Gonzalez RJ, Sondak VK, Sarnaik AA, et al. Atypical fibroxanthoma: outcomes from a large single institution series. Cancer Control. 2023;30:10732748231155699. https://doi.org/10.1177/10732748231155699
  19. Jibbe A, Worley B, Miller CH, Alam M. Surgical excision margins for fibrohistiocytic tumors, including atypical fibroxanthoma and undifferentiated pleomorphic sarcoma: a probability model based on a systematic review. J Am Acad Dermatol. 2022;87(4):833-840.  https://doi.org/10.1016/j.jaad.2021.09.036
  20. Bitel A, Schönlebe J, Krönert C, Wollina U. Atypical fibroxanthoma: an analysis of 105 tumors. Dermatol Ther. 2020;33(6):e13962. https://doi.org/10.1111/dth.13962
  21. Alotaibi Y, Bondagji MF, Alharthi AM, Alharbi A. A rare case of atypical fibroxanthoma of the thigh in an elderly patient. Cureus. 2023;15(1):e33622. https://doi.org/10.7759/cureus.33622
  22. Thway K, Fisher C. Undifferentiated and dedifferentiated soft tissue neoplasms: immunohistochemical surrogates for differential diagnosis. Semin Diagn Pathol. 2021;38(6):170-186.  https://doi.org/10.1053/j.semdp.2021.09.005
  23. Zeller J, Kiefer J, Braig D, Winninger O, Kraus D, Hagelstein S, Eisenhardt SU. Oncological safety and recurrence in the surgical treatment of atypical fibroxanthoma and pleomorphic dermal sarcoma of the scalp. Cancers (Basel). 2022;14(12):2869. https://doi.org/10.3390/cancers14122869
  24. Phan K, Onggo J. Time to recurrence after surgical excision of atypical fibroxanthoma-updated systematic review and meta-analysis. Australas J Dermatol. 2019;60(3):220-222.  https://doi.org/10.1111/ajd.13010
  25. Kolb L, Schmieder GJ. Atypical fibroxanthoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
  26. Monteagudo C, Calduch L, Navarro S, Joan-Figueroa A, Llombart-Bosch A. CD99 immunoreactivity in atypical fibroxanthoma: a common feature of diagnostic value. Am J Clin Pathol. 2002; 117(1):126-131.  https://doi.org/10.1309/2EXB-70CW-3U6P-VQ6H
  27. Carletti M, Nguyen DA, Malouf P, Ingersoll Z, Hosler GA, Weis SE. Pleomorphic dermal sarcoma: a clinical and histopathologic emulator of atypical fibroxanthoma, but different biologic behavior. HCA Healthc J Med. 2022;3(5):299-304.  https://doi.org/10.36518/2689-0216.1334
  28. Gómez-Mateo Mdel C, Monteagudo C. Nonepithelial skin tumors with multinucleated giant cells. Semin Diagn Pathol. 2013;30(1):58-72.  https://doi.org/10.1053/j.semdp.2012.01.004
  29. Jo Vickie Y, Hornick JL. Neoplastic mimics in soft tissue and bone pathology. Demos Medical; 2015.
  30. Lin F, Prichard J, eds. Handbook of practical immunohistochemistry. Frequently asked questions. 2nd ed. New York: Springer science + Business media; 2015. https://doi.org/10.1007/978-1-4939-1578-1
  31. Iglesias-Pena N, Martínez-Campayob N, López-Solache L. Relation between atypical fibroxanthoma and pleomorphic dermal sarcoma: histopathologic features and review of the literature. Actas Dermosifiliogr (Engl Ed). 2021;112(5):392-405.  https://doi.org/10.1016/j.ad.2020.11.018
  32. Soleymani T, Hollmig ST. Conception and management of a poorly understood spectrum of dermatologic neoplasms: atypical fibroxanthoma, pleomorphic dermal sarcoma, and undifferentiated pleomorphic sarcoma. Curr Treat Options Oncol. 2017;18(8):50.  https://doi.org/10.1007/s11864-017-0489-6
  33. Coelho-Lima J, Bruty J, Watkins J, Liu H, Price R, Stefanos N. Clear cell variant of atypical fibroxanthoma and pleomorphic dermal sarcoma: molecular characterization and review of the literature. J Cutan Pathol. 2022;49(12):1031-1034. https://doi.org/10.1111/cup.14307
  34. Kuntz T, Siebdrath J, Hofmann SC, Baltaci M, Schaller J, Hellmich M, von Goltzheim LS, Assaf C, Oellig F, Michalowitz AL, et al. Increase of atypical fibroxanthoma and pleomorphic dermal sarcoma: a retrospective analysis of four German skin cancer centers. J Dtsch Dermatol Ges. 2022;20(12):1581-1588. https://doi.org/10.1111/ddg.14911
  35. Zogbi L, Juliano C, Neutzling A. Atypical fibroxanthoma. J Surg Case Rep. 2015;2015(3):rjv010. https://doi.org/10.1093/jscr/rjv010
  36. Ørholt M, Aaberg FL, Abebe K, Walsh S, Roenigk RK, Venzo A, Schmidt G, Klyver H, Jensen DH, Herly M, et al. Risk factors for local atypical fibroxanthoma recurrence and progression to pleomorphic dermal sarcoma: a meta-analysis of individualized participant data. J Surg Oncol. 2022;126(3):555-562.  https://doi.org/10.1002/jso.26898
  37. Ørholt M, Abebe K, Aaberg F, Rasmussen LE, Daugaard S, Loya AC, Herly M, Vester-Glowinski PV. Immunohistochemical characteristics of atypical fibroxanthoma and pleomorphic dermal sarcoma: a systematic review and meta-analysis. Am J Dermatopathol. 2022;44(12):913-920.  https://doi.org/10.1097/DAD.0000000000002305
  38. Polcz MM, Sebaratnam DF, Fernandez-Penas P. Atypical fibroxanthoma management: recurrence, metastasis and disease-specific death. Australas J Dermatol. 2018;59(1):10-25.  https://doi.org/10.1111/ajd.12646
  39. Tolkachjov SN, Kelley BF, Alahdab F, Erwin PJ, Brewer JD. Atypical fibroxanthoma: systematic review and meta-analysis of treatment with Mohs micrographic surgery or excision. J Am Acad Dermatol. 2018;79(5):929-934.e6.  https://doi.org/10.1016/j.jaad.2018.06.048

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.